L-dopa therapy in Parkinson's disease: a critical review of nine years' experience.
about
Propagation of alpha-synuclein pathology: hypotheses, discoveries, and yet unresolved questions from experimental and human brain studies.Respiration and sleep in Parkinson's diseaseQuantitative Evaluation of Chinese Herb Medicine in the Treatment of Sialorrhea and Frequent Nighttime Urination in Patients with Parkinson's Disease.Amino acid management of Parkinson's disease: a case study.Orofacial dyskinesia. Clinical features, mechanisms and drug therapyFetal stem cell transplantation: Past, present, and future.Maladaptive reward-learning and impulse control disorders in patients with Parkinson's disease: a clinical overview and pathophysiology updateDetermination of Serotonin and Dopamine Metabolites in Human Brain Microdialysis and Cerebrospinal Fluid Samples by UPLC-MS/MS: Discovery of Intact Glucuronide and Sulfate Conjugates.Paraphilias and paraphilic disorders in Parkinson's disease: A systematic review of the literature.Permeation of Dopamine Sulfate through the Blood-Brain Barrier.Complete Comparison Display (CCD) evaluation of ethanol extracts of Centella asiatica and Withania somnifera shows that they can non-synergistically ameliorate biochemical and behavioural damages in MPTP induced Parkinson's model of miceExpression of Tgfβ1 and Inflammatory Markers in the 6-hydroxydopamine Mouse Model of Parkinson's Disease.Recognition and management of neuropsychiatric complications in Parkinson's disease.Speech disorders of Parkinsonism: a review.Plasma DOPA levels and growth hormone response to levodopa in parkinsomismAttempted use of haloperidol in the treatment of L-dopa induced dyskinesiasThe management of orthostatic hypotension in Parkinson's disease.The history of Parkinson's disease: early clinical descriptions and neurological therapies.Severity of Parkinson's disease is a risk factor for peak-dose dyskinesia.Backward walking and circling: behavioural responses induced by drug treatments which cause simultaneous release of catecholamines and 5-hydroxytryptamine.Parkinson's disease: carbidopa, nausea, and dyskinesia.Current understanding of the molecular mechanisms in Parkinson's disease: Targets for potential treatments.
P2860
Q27322513-3B33FA45-218D-4DA8-B73D-B54A1A96E77EQ33621726-7AFECD64-8C41-4E40-8FE5-ECF8C39CB5AAQ33623832-203756EC-DC61-4E8B-B438-C7E18DF091F2Q34026440-81DFBED3-6F09-4945-A076-FDD0AA7A8868Q34050289-125BFD08-73D2-4A67-AD55-AC578622BA8DQ34232844-8CBF77DC-7345-45FE-80E5-A32948022E0FQ34423280-7127A652-100C-41E2-B92F-AA33FFF77C05Q34797658-22406A47-26EB-4C05-ABCC-9A1FC4616CC6Q35595866-2A217C1E-87CB-492E-A7D1-7DD1CE9EF427Q35710747-4F2F5FFD-9435-460B-9BF8-B38B9CE46BA0Q36373173-B41D7A17-BD19-40E4-A5B4-EE009EFE9240Q36534782-636EBA09-CC32-4966-848C-B9708E2E4EAAQ36673715-B74D3349-6B9D-4CDF-84DE-FF220F89C666Q37014233-D2F471AE-2AD7-47EF-A892-FF3F9EDADD18Q37050411-EA7EE026-6633-4AFF-9334-34CFDF7DA138Q37098380-827CEB9D-860F-4CFB-B05E-77BF4EA1F16EQ38114882-0484511B-4858-42F1-A2A6-4B28FD2509B9Q39699761-C14BD795-5A68-4791-8C35-5FE0B2FE0F08Q41591036-80502B92-3119-4931-A858-BFD104965D15Q41727104-42232A2A-2232-4FF2-A09A-0C2D84149439Q41780193-1A5F0265-D16A-4F36-BECD-76B5E6695398Q45873810-395F9FFA-E959-4C65-AF1D-0702E8A6565D
P2860
L-dopa therapy in Parkinson's disease: a critical review of nine years' experience.
description
1969 nî lūn-bûn
@nan
1969年の論文
@ja
1969年論文
@yue
1969年論文
@zh-hant
1969年論文
@zh-hk
1969年論文
@zh-mo
1969年論文
@zh-tw
1969年论文
@wuu
1969年论文
@zh
1969年论文
@zh-cn
name
L-dopa therapy in Parkinson's disease: a critical review of nine years' experience.
@ast
L-dopa therapy in Parkinson's disease: a critical review of nine years' experience.
@en
type
label
L-dopa therapy in Parkinson's disease: a critical review of nine years' experience.
@ast
L-dopa therapy in Parkinson's disease: a critical review of nine years' experience.
@en
prefLabel
L-dopa therapy in Parkinson's disease: a critical review of nine years' experience.
@ast
L-dopa therapy in Parkinson's disease: a critical review of nine years' experience.
@en
P2860
P1476
L-dopa therapy in Parkinson's disease: a critical review of nine years' experience
@en
P2093
P2860
P407
P577
1969-12-01T00:00:00Z